SRP5030
FGFR2 (285-end), active, GST tagged human
PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥80% (SDS-PAGE), buffered aqueous glycerol solution
Synonym(s):
BFR-1, CD332, CEK3, ECT1, JWS, K-SAM, TK14, TK25
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
recombinant
expressed in baculovirus infected Sf9 cells
product line
PRECISIO® Kinase
assay
≥80% (SDS-PAGE)
form
buffered aqueous glycerol solution
specific activity
100-136 nmol/min·mg
mol wt
~72 kDa
NCBI accession no.
shipped in
dry ice
storage temp.
−70°C
Gene Information
human ... FGFR2(2263)
General description
FGFR2 is a member of the fibroblast growth factor receptor family which play a role in mitogenesis and differentiation. FGFR2 is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, and mutations in FGFR2 are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. FGFR2 is required for early postimplantation development between implantation and the formation of the egg cylinder. FGFR2 contributes to the outgrowth, differentiation, and maintenance of the inner cell mass.
Physical form
Supplied in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.
Preparation Note
after opening, aliquot into smaller quantities and store at -70 °C. Avoid repeating handling and multiple freeze/thaw cycles
Legal Information
PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
10 - Combustible liquids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
American journal of human genetics, 70(2), 472-486 (2002-01-10)
It has been known for several years that heterozygous mutations of three members of the fibroblast growth-factor-receptor family of signal-transduction molecules-namely, FGFR1, FGFR2, and FGFR3-contribute significantly to disorders of bone patterning and growth. FGFR3 mutations, which predominantly cause short-limbed bone
Proceedings of the National Academy of Sciences of the United States of America, 95(9), 5082-5087 (1998-06-06)
We disrupted the fibroblast growth factor (FGF) receptor 2 (FGFR2) gene by introducing a neo cassette into the IIIc ligand binding exon and by deleting a genomic DNA fragment encoding its transmembrane domain and part of its kinase I domain.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service